Esperion Therapeutics, Inc. ESPR
We take great care to ensure that the data presented and summarized in this overview for Esperion Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ESPR
View all-
Orbimed Advisors LLC San Diego, CA13.7MShares$41 Million0.83% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$29.7 Million0.42% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT9.13MShares$27.3 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.83MShares$26.4 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT8MShares$23.9 Million5.25% of portfolio
-
Woodline Partners LP San Francisco, CA7.92MShares$23.7 Million0.2% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.68MShares$17 Million0.01% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY5.14MShares$15.4 Million0.01% of portfolio
-
Bank Of America Corp Charlotte, NC4.55MShares$13.6 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY4.17MShares$12.5 Million5.73% of portfolio
Latest Institutional Activity in ESPR
Top Purchases
Top Sells
About ESPR
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Transactions at ESPR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Joanne M. Foody Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,285
-1.19%
|
$6,570
$2.87 P/Share
|
|
Jun 18
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,540
-1.51%
|
$5,080
$2.86 P/Share
|
|
May 23
2024
|
Jay Shepard Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+30.83%
|
-
|
|
May 23
2024
|
Stephen Rocamboli Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+38.81%
|
-
|
|
May 23
2024
|
Antonio M Jr Md D Phil Gotto Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+30.83%
|
-
|
|
May 23
2024
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+30.1%
|
-
|
|
May 23
2024
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+44.97%
|
-
|
|
May 23
2024
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,000
+26.24%
|
-
|
|
May 17
2024
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
192
-0.11%
|
$384
$2.48 P/Share
|
|
Mar 14
2024
|
Eric Warren Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+37.27%
|
-
|
|
Mar 14
2024
|
Sheldon L. Koenig President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
454,000
+37.19%
|
-
|
|
Mar 14
2024
|
Benjamin Looker General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+35.25%
|
-
|
|
Mar 14
2024
|
Joanne M. Foody Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+35.12%
|
-
|
|
Mar 14
2024
|
Benjamin Halladay Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
170,000
+41.07%
|
-
|
|
Sep 20
2023
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
742
-1.07%
|
$742
$1.25 P/Share
|
|
Aug 18
2023
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
243
-0.35%
|
$243
$1.41 P/Share
|
|
Jul 19
2023
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
106
-0.15%
|
$106
$1.58 P/Share
|
|
Jun 21
2023
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
603
-0.86%
|
$603
$1.48 P/Share
|
|
Jun 15
2023
|
Alan Fuhrman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,150
+14.49%
|
-
|
|
Jun 15
2023
|
Antonio M Jr Md D Phil Gotto Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,150
+15.26%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.11M shares |
|---|
| Open market or private sale | 7.11K shares |
|---|